Literature DB >> 15338274

Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload.

Monique G Zaahl1, Alison T Merryweather-Clarke, Maritha J Kotze, Schalk van der Merwe, Louise Warnich, Kathryn J H Robson.   

Abstract

Extensive investigation into the molecular basis of iron overload disorders has provided new insights into the complexity of iron metabolism and related cellular pathways. The possible involvement of genes affecting iron homeostasis, including HFE, SLC40A1, HAMP and CYBRD1, was investigated in individuals who were referred for confirmation or exclusion of a diagnosis of haemochromatosis, but who tested negative or were heterozygous for the causative HFE mutation, C282Y. Denaturing high performance liquid chromatography analysis of these genes revealed a unique spectrum of mutations in the South African study population, including 67 unrelated patients and 70 population-matched controls. Two novel CYBRD1 gene mutations, R226H and IVS1-4C-->G, were identified in 11% of South African Caucasian patient referrals. We identified a novel D270V mutation in the SLC40A1 gene in a Black South African female with iron overload. These mutations were absent in the control population. In Africans with iron overload not related to the HFE gene, the possible involvement of the SLC40A1 and CYBRD1 genes was demonstrated for the first time. This study confirms the genetic heterogeneity of haemochromatosis and highlights the significance of CYBRD1 mutations in relation to iron overload.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338274     DOI: 10.1007/s00439-004-1166-y

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  50 in total

1.  Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression.

Authors:  S Borrego; M E Sáez; A Ruiz; O Gimm; M López-Alonso; G Antiñolo; C Eng
Journal:  J Med Genet       Date:  1999-10       Impact factor: 6.318

2.  A new polymorphism in the human HFE gene.

Authors:  T Höhler; S Leininger; P M Schneider
Journal:  Immunogenetics       Date:  1999-08       Impact factor: 2.846

3.  Identification of 96 single nucleotide polymorphisms in eight genes involved in iron metabolism: efficiency of bioinformatic extraction compared with a systematic sequencing approach.

Authors:  V Douabin-Gicquel; N Soriano; H Ferran; F Wojcik; E Palierne; S Tamim; T Jovelin; A T McKie; J Y Le Gall; V David; J Mosser
Journal:  Hum Genet       Date:  2001-10       Impact factor: 4.132

4.  A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.

Authors:  O T Njajou; N Vaessen; M Joosse; B Berghuis; J W van Dongen; M H Breuning; P J Snijders; W P Rutten; L A Sandkuijl; B A Oostra; C M van Duijn; P Heutink
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

5.  New diallelic markers in the HLA region of chromosome 6.

Authors:  E Beutler; C West
Journal:  Blood Cells Mol Dis       Date:  1997-08       Impact factor: 3.039

Review 6.  Splicing of messenger RNA precursors.

Authors:  R A Padgett; P J Grabowski; M M Konarska; S Seiler; P A Sharp
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

7.  Uncommon mutations and polymorphisms in the hemochromatosis gene.

Authors:  J J Pointon; D Wallace; A T Merryweather-Clarke; K J Robson
Journal:  Genet Test       Date:  2000

8.  Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors.

Authors:  J F Cáceres; S Stamm; D M Helfman; A R Krainer
Journal:  Science       Date:  1994-09-16       Impact factor: 47.728

9.  Expression of the SLC11A1 (NRAMP1) 5'-(GT)n repeat: opposite effect in the presence of -237C-->T.

Authors:  Monique G Zaahl; Kathryn J H Robson; Louise Warnich; Maritha J Kotze
Journal:  Blood Cells Mol Dis       Date:  2004 Jul-Aug       Impact factor: 3.039

10.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.

Authors:  Antonella Roetto; George Papanikolaou; Marianna Politou; Federica Alberti; Domenico Girelli; John Christakis; Dimitris Loukopoulos; Clara Camaschella
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

View more
  9 in total

1.  Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.

Authors:  Sharraya Aschemeyer; Bo Qiao; Deborah Stefanova; Erika V Valore; Albert C Sek; T Alex Ruwe; Kyle R Vieth; Grace Jung; Carla Casu; Stefano Rivella; Mika Jormakka; Bryan Mackenzie; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2017-12-13       Impact factor: 22.113

2.  Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination.

Authors:  Bo Qiao; Priscilla Sugianto; Eileen Fung; Alejandro Del-Castillo-Rueda; Maria-Josefa Moran-Jimenez; Tomas Ganz; Elizabeta Nemeth
Journal:  Cell Metab       Date:  2012-06-06       Impact factor: 27.287

3.  Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin.

Authors:  Sergei Nekhai; Min Xu; Altreisha Foster; Ishmael Kasvosve; Sharmin Diaz; Roberto F Machado; Oswaldo L Castro; Gregory J Kato; James G Taylor; Victor R Gordeuk
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 4.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

5.  Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.

Authors:  Roman Mayr; Andreas R Janecke; Melanie Schranz; William J H Griffiths; Wolfgang Vogel; Antonello Pietrangelo; Heinz Zoller
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

6.  DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms.

Authors:  David J Lemler; Miranda L Lynch; Lia Tesfay; Zhiyong Deng; Bibbin T Paul; Xiaohong Wang; Poornima Hegde; David H Manz; Suzy V Torti; Frank M Torti
Journal:  Breast Cancer Res       Date:  2017-03-07       Impact factor: 6.466

7.  The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data.

Authors:  Daniel F Wallace; V Nathan Subramaniam
Journal:  Genet Med       Date:  2015-12-03       Impact factor: 8.822

Review 8.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

Review 9.  Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features.

Authors:  L Tom Vlasveld; Roel Janssen; Edouard Bardou-Jacquet; Hanka Venselaar; Houda Hamdi-Roze; Hal Drakesmith; Dorine W Swinkels
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.